Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 17

Results For "tolerability"

200 News Found

Pfizer and BioNTech evaluate Omicron specific Covid-19 vaccine
News | January 25, 2022

Pfizer and BioNTech evaluate Omicron specific Covid-19 vaccine

First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose


Biogen exercises option with Ionis for spinal muscular atrophy
Biotech | January 05, 2022

Biogen exercises option with Ionis for spinal muscular atrophy

Biogen paid Ionis a US $ 60 million one-time upfront payment


Kyverna Therapeutics announces licence agreement with NIH
Biotech | January 04, 2022

Kyverna Therapeutics announces licence agreement with NIH

This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel


Celltrion announces positive results for its cocktail Covid-19 therapy candidates
Biotech | January 03, 2022

Celltrion announces positive results for its cocktail Covid-19 therapy candidates

Celltrion plans to provide dual treatment options for COVID-19; Regkirona for hospitalised patients and a nebulised cocktail therapy (CT-P63 in combination with Regkirona) for at- home settings


Biocon partner Equillium initiates clinical study for Itolizumab in Lupus Nephritis
Biotech | December 24, 2021

Biocon partner Equillium initiates clinical study for Itolizumab in Lupus Nephritis

Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000


U.S. FDA approves first and only injectable option for HIV prevention
Drug Approval | December 21, 2021

U.S. FDA approves first and only injectable option for HIV prevention

Given as few as six times per year and demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of HIV acquisition


Zydus to begin Phase II (a) clinical trial of ZYIL1 in Australia
Biotech | December 13, 2021

Zydus to begin Phase II (a) clinical trial of ZYIL1 in Australia

It is a novel oral NLRP3 inflammasome inhibitor


Moderna seeks approval from EMA for its Covid-19 vaccine for children between 6-11 years
News | November 10, 2021

Moderna seeks approval from EMA for its Covid-19 vaccine for children between 6-11 years

The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11


Novavax files emergency use listing with WHO for Covid-19 vaccine
Biotech | November 05, 2021

Novavax files emergency use listing with WHO for Covid-19 vaccine

All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO


Lancet endorses Sputnik Light for safety and immune response
News | November 03, 2021

Lancet endorses Sputnik Light for safety and immune response

Sputnik Light has been authorised in more than 15 countries with the registration process ongoing in a further 30 countries